128 related articles for article (PubMed ID: 37844759)
21. Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model.
Wang J; Giragossian C; Hansel S
Eur J Pharm Biopharm; 2021 Nov; 168():110-121. PubMed ID: 34478854
[TBL] [Abstract][Full Text] [Related]
22. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
[TBL] [Abstract][Full Text] [Related]
24. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
25. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies.
Maron R; Schechter B; Nataraj NB; Ghosh S; Romaniello D; Marrocco I; Noronha A; Carvalho S; Yarden Y; Sela M
Biochem Biophys Res Commun; 2019 May; 513(1):219-225. PubMed ID: 30952434
[TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
[TBL] [Abstract][Full Text] [Related]
28. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
Yao HP; Hudson R; Wang MH
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
[TBL] [Abstract][Full Text] [Related]
29. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
30. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.
Quatannens D; Verhoeven Y; Van Dam P; Lardon F; Prenen H; Roeyen G; Peeters M; Smits ELJ; Van Audenaerde J
Pharmacol Ther; 2022 Aug; 236():108107. PubMed ID: 34999181
[TBL] [Abstract][Full Text] [Related]
31. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
32. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
33. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer.
Onishi H; Kai M; Odate S; Iwasaki H; Morifuji Y; Ogino T; Morisaki T; Nakashima Y; Katano M
Cancer Sci; 2011 Jun; 102(6):1144-50. PubMed ID: 21338440
[TBL] [Abstract][Full Text] [Related]
35. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
36. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer.
Miyamoto R; Oda T; Hashimoto S; Kurokawa T; Inagaki Y; Shimomura O; Ohara Y; Yamada K; Akashi Y; Enomoto T; Kishimoto M; Yanagihara H; Kita E; Ohkohchi N
Cancer Sci; 2016 Apr; 107(4):514-20. PubMed ID: 26782353
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
39. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Calomme A; Demetter P; Delpero JR; Svrcek M; Cros J; Bardier-Dupas A; Puleo F; Monges G; Hammel P; Louvet C; Paye F; Bachelier P; Le Treut YP; Vaillant JC; Sauvanet A; André T; Salmon I; Devière J; Emile JF; Van Laethem JL
Clin Cancer Res; 2015 Mar; 21(5):1215-24. PubMed ID: 25552484
[TBL] [Abstract][Full Text] [Related]
40. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
